RESUMEN
We present a drug design strategy based on structural knowledge of protein-protein interfaces selected through virus-host coevolution and translated into highly potential small molecules. This approach is grounded on Vinland, the most comprehensive atlas of virus-human protein-protein interactions with annotation of interacting domains. From this inspiration, we identified small viral protein domains responsible for interaction with human proteins. These peptides form a library of new chemical entities used to screen for replication modulators of several pathogens. As a proof of concept, a peptide from a KSHV protein, identified as an inhibitor of influenza virus replication, was translated into a small molecule series with low nanomolar antiviral activity. By targeting the NEET proteins, these molecules turn out to be of therapeutic interest in a nonalcoholic steatohepatitis mouse model with kidney lesions. This study provides a biomimetic framework to design original chemistries targeting cellular proteins, with indications going far beyond infectious diseases.
Asunto(s)
Gripe Humana , Virus , Animales , Ratones , Humanos , Proteoma , Péptidos/farmacología , Descubrimiento de DrogasRESUMEN
Here, we describe the identification and synthesis of novel indole sulfonamide derivatives that activate the three peroxisome proliferator activated receptor (PPAR) isoforms. Starting with a PPARα activator, compound 4, identified during a high throughput screening (HTS) of our proprietary screening library, a systematic optimization led to the discovery of lanifibranor (IVA337) 5, a moderately potent and well balanced pan PPAR agonist with an excellent safety profile. In vitro and in vivo, compound 5 demonstrated strong activity in models that are relevant to nonalcoholic steatohepatitis (NASH) pathophysiology suggesting therapeutic potential for NASH patients.
Asunto(s)
Benzotiazoles/síntesis química , Benzotiazoles/farmacología , Fibrosis/prevención & control , Indoles/síntesis química , Indoles/farmacología , Receptores Activados del Proliferador del Peroxisoma/agonistas , Sulfonamidas/síntesis química , Sulfonamidas/farmacología , Animales , Benzotiazoles/farmacocinética , Intoxicación por Tetracloruro de Carbono/tratamiento farmacológico , Línea Celular , Descubrimiento de Drogas , Hepatocitos/efectos de los fármacos , Ensayos Analíticos de Alto Rendimiento , Humanos , Hipoglucemiantes/síntesis química , Hipoglucemiantes/farmacología , Indoles/farmacocinética , Ratones , Ratones Endogámicos C57BL , Modelos Moleculares , Estructura Molecular , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Sulfonamidas/farmacocinéticaRESUMEN
Apelin plays a prominent role in body fluid and cardiovascular homeostasis. To explore further upstream the role played by this peptide, nonpeptidic agonists and antagonists of the apelin receptor are required. To identify such compounds that do not exist to date, we used an original fluorescence resonance energy transfer-based assay to screen a G-protein-coupled receptor-focused library of fluorescent compounds on the human EGFP-tagged apelin receptor. This led to isolated E339-3D6 that displayed a 90 nM affinity and behaved as a partial agonist with regard to cAMP production and as a full agonist with regard to apelin receptor internalization. Finally, E339-3D6 induced vasorelaxation of rat aorta precontracted with noradrenaline and potently inhibited systemic vasopressin release in water-deprived mice when intracerebroventricularly injected. This compound represents the first nonpeptidic agonist of the apelin receptor, the optimization of which will allow development of a new generation of vasodilator and aquaretic agents.
Asunto(s)
Dipéptidos/farmacología , Fluoresceínas/farmacología , Receptores Acoplados a Proteínas G/agonistas , Animales , Aorta/efectos de los fármacos , Receptores de Apelina , Colforsina/farmacología , AMP Cíclico/metabolismo , Dipéptidos/química , Dipéptidos/aislamiento & purificación , Evaluación Preclínica de Medicamentos/métodos , Fluoresceínas/química , Fluoresceínas/aislamiento & purificación , Transferencia Resonante de Energía de Fluorescencia/métodos , Humanos , Masculino , Ratones , Ratas , Ratas Endogámicas WKY , Vasodilatación , Vasopresinas/metabolismoRESUMEN
The efficiency of fluorescence resonance energy transfer (FRET) is dependent upon donor-acceptor proximity and spectral overlap, whether the acceptor partner is fluorescent or not. We report here on the design, synthesis, and characterization of two novel pirenzepine derivatives that were coupled to patent blue VF and pinacyanol dyes. These nonfluorescent compounds, when added to cells stably expressing enhanced green fluorescent protein (EGFP)-fused muscarinic M1 receptors, promote EGFP fluorescence extinction in a time-, concentration-, and atropine-dependent manner. They display nanomolar affinity for the muscarinic receptor, determined using either FRET or classical radioligand binding conditions. We provide evidence that these compounds behave as potent acceptors of energy from excited EGFP with quenching efficiencies comparable to those of analogous fluorescent bodipy or rhodamine red pirenzepine derivatives. The advantages they offer over fluorescent ligands are illustrated and discussed in terms of reliability, sensitivity, and wider applicability of FRET-based receptor binding assays.
Asunto(s)
Bencenosulfonatos/síntesis química , Benzodiazepinonas/síntesis química , Colorantes/síntesis química , Proteínas Fluorescentes Verdes/metabolismo , Pirenzepina/análogos & derivados , Pirenzepina/síntesis química , Compuestos de Quinolinio/síntesis química , Receptor Muscarínico M1/metabolismo , Proteínas Recombinantes de Fusión/metabolismo , Bencenosulfonatos/química , Benzodiazepinonas/química , Compuestos de Boro , Línea Celular , Colorantes/química , Transferencia Resonante de Energía de Fluorescencia , Proteínas Fluorescentes Verdes/genética , Humanos , Ligandos , Pirenzepina/química , Compuestos de Quinolinio/química , Ensayo de Unión Radioligante , Receptor Muscarínico M1/genética , Proteínas Recombinantes de Fusión/genéticaRESUMEN
Following a recent description of fluorescence resonance energy transfer between enhanced green fluorescent protein (EGFP)-fused human muscarinic M1 receptors and Bodipy-labeled pirenzepine, we synthesized seven fluorescent derivatives of this antagonist in order to further characterize ligand-receptor interactions. These compounds carry Bodipy [558/568], Rhodamine Red-X [560/580], or Fluorolink Cy3 [550/570] fluorophores connected to pirenzepine through various linkers. All molecules reversibly bind with high affinity to M1 receptors (radioligand and energy transfer binding experiments) provided that the linker contains more than six atoms. The energy transfer efficiency exhibits modest variations among ligands, indicating that the distance separating EGFP from the fluorophores remains almost constant. This also supports the notion that the fluorophores may bind to the receptor protein. Kinetic analyses reveal that the dissociation of two Bodipy derivatives (10 or 12 atom long linkers) is sensitive to the presence of the allosteric modulator brucine, while that of all other molecules (15-24 atom long linkers) is not. The data favor the idea that these analogues might interact with both the acetylcholine and the brucine binding domains.